GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » Shares Outstanding (EOP)

SNPHY (Santen Pharmaceutical Co) Shares Outstanding (EOP) : 349 Mil (As of Sep. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Santen Pharmaceutical Co's shares outstanding for the quarter that ended in Sep. 2024 was 349 Mil.

Santen Pharmaceutical Co's quarterly shares outstanding declined from Jun. 2024 (356 Mil) to Sep. 2024 (349 Mil). It means Santen Pharmaceutical Co bought back shares from Jun. 2024 to Sep. 2024 .

Santen Pharmaceutical Co's annual shares outstanding declined from Mar. 2023 (376 Mil) to Mar. 2024 (363 Mil). It means Santen Pharmaceutical Co bought back shares from Mar. 2023 to Mar. 2024 .


Santen Pharmaceutical Co Shares Outstanding (EOP) Historical Data

The historical data trend for Santen Pharmaceutical Co's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Shares Outstanding (EOP) Chart

Santen Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 399.42 399.82 400.27 375.54 363.21

Santen Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 366.99 363.19 363.21 355.65 349.15

Competitive Comparison of Santen Pharmaceutical Co's Shares Outstanding (EOP)

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co's Shares Outstanding (EOP) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Shares Outstanding (EOP) falls into.



Santen Pharmaceutical Co Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Santen Pharmaceutical Co  (OTCPK:SNPHY) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Santen Pharmaceutical Co Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Santen Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co Headlines